One group of these novel compounds works by inhibiting Cyclin Dependent Kinases
(CDK), drug targets that control cancer cell division.
United States Patent 6,531,479 relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin dependent kinases
(CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukemia, psoriasis and the like.
The Company remains on track with enrollment of the Phase IIb, multi-center, randomized, double-blinded APPRAISE trial which is evaluating the efficacy and safety of the investigational drug seliciclib (CYC202), an orally-available molecule that targets cyclin dependent kinases
(CDKs), as a third-line treatment in patients with non-small cell lung cancer (NSCLC).
As an extremely promising new class of enzyme targets, the cyclin dependent kinases
have precisely defined roles in the cell division process, and are altered in many cancers," said Paul Friedman, President, Research and Development, DuPont Merck.
Nasdaq: CYCC) announced today that the company is beginning a Phase IIb, multi-center, randomized, double-blinded trial to evaluate the efficacy and safety of the investigational drug seliciclib (CYC202), an orally available molecule that targets cyclin dependent kinases
(CDKs), as a third line treatment in patients with non-small cell lung cancer (NSCLC).
The cyclin E license will become part of Mitotix's current drug discovery program to develop novel treatments that regulate the cell cycle through inhibition of cyclin dependent kinases
Paracelsian's team of scientists discovered that there is a consistent relationship between cyclin dependent kinase
concentrations and cell growth and proliferation.